Pharmacodynamic considerations with recombinant human insulin-like growth factor-I in children

Hormone Research

Volumn 63, Issue 5, 2005, Pages 220-227

  Ferry Jr , Robert J ^a,b   Cohen, Pinchas ^c   Katz, Lorraine E Levitt ^d,e  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b 2nd Battalion   (Iraq)

^c MATTEL CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Hyperinsulinism; IGF I; IGF I dosing; IGFBP; Pharmacokinetics; rhIGF I dosing

Indexed keywords

RECOMBINANT SOMATOMEDIN C; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 3;

ARTICLE; BODY SURFACE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CORRELATION ANALYSIS; DOSE CALCULATION; DOSE RESPONSE; FEMALE; HUMAN; HYPERINSULINEMIA; INFANT; LINEAR REGRESSION ANALYSIS; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY;

BODY SURFACE AREA; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; HYPERINSULINISM; INFANT; INJECTIONS, SUBCUTANEOUS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 2; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; MALE; RECOMBINANT PROTEINS;

EID: 22544478799     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000085682     Document Type: Article

References (48)

1. Ferry RJ Jr, Cohen P: The insulin-like growth factor axis in pediatrics. Clin Pediatr Endocrinol 1999;8:1-10.
2. Mauras N, Martinez V, Rini A, Guevara-Aguirre J: Recombinant human insulin-like growth factor I has significant anabolic effects in adults with growth hormone receptor deficiency: Studies on protein, glucose, and lipid metabolism. J Clin Endocrinol Metab 2000;85:3036-3042.
3. Walker JL, Ginalska-Malinowksa M, Romer TE, Pucilowska JB, Underwood LE: Effects of the infusion of insulin-like growth factor I in a child with growth hormone insensitivity (Laron dwarfism). N Engl J Med 1991;324:1483-1488.
4. Vaccarello MA, Diamond FB Jr, Guevara-Aguirre J, Rosenbloom AL, Fielder PJ, Gargosky S, Cohen P, Wilson K, Rosenfeld RG: Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency/Laron syndrome. J Clin Endocrinol Metab 1993;77:273-280.
5. Thrailkill KM, Quattrin T, Baker L, Kuntze JE, Compton PG, Martha PM Jr: Cotherapy with recombinant human insulin-like growth factor I and insulin improves glycemic control in type 1 diabetes. Diabetes Care 1999;22:585-592.
6. Crowne EC, Samra JS, Cheetham T, Watts A, Holly JM, Dunger DB: Recombinant human insulin-like growth factor-I abolishes changes in insulin requirements consequent upon growth hormone pulsatility in young adults with type I diabetes mellitus. Metabolism 1998;47:31-38.
7. Cioffi WG, Gore DC, Rue LW 3rd, Carrougher G, Guler HP, McManus WF, Pruitt BA Jr: Insulin-like growth factor-1 lowers protein oxidation in patients with thermal injury. Ann Surg 1994;220:310-319.
8. Clemmons DR, Smith-Banks A, Underwood LE: Reversal of diet-induced catabolism by infusion of recombinant insulin-like growth factor-I in humans. J Clin Endocrinol Metab 1992;75:234-238.
9. Waters D, Danska J, Hardy K, Koster F, Qualls C, Nickell D, Nightingale S, Gesundheit N, Watson D, Schade D: Recombinant human growth hormone, insulin-like growth factor 1 and combination therapy in AIDS-associated wasting. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1996;125:865-872.
10. Herndon DN, Ramzy PI, DebRoy MA, Zheng M, Ferrando AA, Chinkes DL, Barret JP, Wolfe RR, Wolf SE: Muscle protein catabolism after severe burn: effects of IGF-1/IGFBP-3 treatment. Ann Surg 1999;229:713-720.
11. Kuzuya H, Matsuura N, Sakamoto M, Makino H, Sakamoto Y, Kadowaki T, Suzuki Y, Kobayashi M, Akazawa Y, Nomura M, et al: Trial of insulin-like growth factor I therapy for patients with extreme insulin resistance syndromes. Diabetes 1993;42:696-705.
12. Vestergaard H, Rossen M, Urhammer SA, Muller J, Pedersen O: Short- and long-term metabolic effects of recombinant human IGF-I treatment in patients with severe insulin resistance and diabetes mellitus. Eur J Endocrinol 1997;136:475-482.
13. Zenobi PD, Glatz Y, Keller A, Graf S, Jaeggi-Groisman SE, Riesen WF, Schoenle EJ, Froesch ER: Beneficial metabolic effects of insulin-like growth factor I in patients with severe insulin-resistant diabetes type A. Eur J Endocrinol 1994;131:251-257.
14. Katz LEL, Ferry RJ Jr, Stanley CA, Collett-Solberg PF, Baker L, Cohen P: Suppression of insulin over-secretion by subcutaneous recombinant human insulin-like growth factor-I in children with congenital hyperinsulinism due to defective β-cell sulfonylurea receptor. J Clin Endocrinol Metab 1999;84:3117-3124.
15. Spies M, Wolf SE, Barrow RE, Jeschke MG, Herndon DN: Modulation of types I and II acute phase reactants with insulin-like growth factor-1/binding protein-3 complex in severely burned children. Crit Care Med 2002;30:83-88.
16. Underwood LE, Backeljauw P, Duncan V: Effects of insulin-like growth factor I treatment on statural growth, body composition and phenotype of children with growth hormone insensitivity syndrome. GHIS Collaborative Group. Acta Paediatr Suppl 1999;88:182-184.
17. Acerini CL, Harris DA, Matyka KA, Watts AP, Umpleby AM, Russell-Jones DL, Dunger DB: Effects of low-dose recombinant human insulin-like growth factor-I on insulin sensitivity, growth hormone and glucagon levels in young adults with insulin-dependent diabetes mellitus. Metabolism 1998;47:1481-1489.
18. Acerini CL, Patton CM, Savage MO, Kernell A, Westphal O, Dunger DB: Randomised placebo-controlled trial of human recombinant insulin-like growth factor I plus intensive insulin therapy in adolescents with insulin-dependent diabetes mellitus. Lancet 1997;350:1199-1204.
19. Batch JA, Baxter RC, Werther G: Abnormal regulation of insulin-like growth factor binding proteins in adolescents with insulin-dependent diabetes. Clin Endocrinol Metab 1991;73:964-968.
20. Finegold DN, Stanley CA, Baker L: Glycemic response to glucagon during fasting hypoglycemia: An aid in the diagnosis of hyperinsulinism. J Pediatr 1980;96:257-259.
21. Hussain K, Aynsley-Green A: Management of hyperinsulinism in infancy and childhood. Ann Med 2000;32:544-551.
22. Lovvorn HN 3rd, Nance ML, Ferry RJ Jr, Stolte L, Baker L, O'Neill JA Jr, Schnaufer L, Stanley CA, Adzick NS: Congenital hyperinsulinism and the surgeon: Lessons learned over 35 years. J Pediatr Surg 1999;34:786-793.
23. Lack JA, Stuart-Taylor ME: Calculation of drug dosage and body surface area of children. Br J Anaesth 1997;78:601-605; erratum in Br J Anaesth 1997;79:268.
24. Briars GL, Bailey BJ: Surface area estimation: Pocket calculator vs. nomogram. Arch Dis Child 1994;70:246-247.
25. Nestorowicz A, Wilson BA, Schoor KP, Inoue H, Glaser B, Landau H, Stanley CA, Thornton PS, Clement JP 4th, Bryan J, Aguilar-Bryan L, Permutt MA: Mutations in the sulfonylurea receptor gene are associated with familial hyperinsulinism in Ashkenazi Jews. Hum Mol Genet 1996;5:1813-1822.
26. Thomas P, Ye Y, Lightner E: Mutation of the pancreatic islet inward rectifier Kir6.2 also leads to familial persistent hyperinsulinemic hypoglycemia of infancy. Hum Mol Genet 1996;5:1809-1812.
27. Katz LEL, Satin-Smith MS, Collett-Solberg P, et al: Insulin-like growth factor binding protein-1 levels in the diagnosis of hypoglycemia due to hyperinsulinism. J Pediatr 1997;131:193-199.
28. Wilton P, Sietnieks A, Gunnarsson R, Berger L, Grahnen A: Pharmacokinetic profile of recombinant human insulin-like growth factor I given subcutaneously in normal subjects. Acta Paediatr Scand 1991;377:111-114.
29. Oscarsson J, Lundstam U, Gustafsson B, Wilton P, Eden S, Wiklund O: Recombinant human insulin-like growth factor-I decreases serum lipoprotein(a) concentrations in normal adult men. Clin Endocrinol 1995;42:673-676.
30. Zenobi PD, Graf S, Ursprung H, Froesch ER: Effects of insulin-like growth factor-I on glucose tolerance, insulin levels, and insulin secretion. J Clin Invest 1992;89:1908-1913.
31. Gelander L, Blum WF, Larsson L, Rosberg S, Albertsson-Wikland K: Monthly measurements of insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in healthy prepubertal children: Characterization and relationship with growth: the 1-year growth study. Pediatr Res 1999;45:377-383.
32. Blum WF, Ranke MB: Use of insulin-like growth factor-binding protein 3 for the evaluation of growth disorders. Horm Res 1990;33:31-37.
33. Juul A, Dalgaard P, Blum WF, Bang P, Hall K, Michaelsen KF, Muller J, Skakkebaek NE: Serum levels of insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) in healthy infants, children, and adolescents: The relation to IGF-I, IGF-II, IGFBP-I, IGFBP-2, age, sex, body mass index, and pubertal maturation. J Clin Endocrinol Metab 1995;80:2534-2542.
34. Guevara-Aguirre J, Vasconez O, Martinez V, Martinez AL, Rosenbloom AL, Diamond FB Jr, Gargosky SE, Nonoshita L, Rosenfeld RG: A randomized, double-blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency. J Clin Endocrinol Metab 1995;80:1393-1398.
35. Ranke MB, Savage MO, Chatelain PG, Preece MA, Rosenfeld RG, Wilton P: Long-term treatment of growth hormone insensitivity syndrome with IGF-I. Results of the European Multicentre Study. The Working Group on Growth Hormone Insensitivity Syndromes. Horm Res 1999;51:128-134.
36. Nakae J, Kato M, Murashita M, Shinohara N, Tajima T, Fujieda K: Long-term effect of recombinant human insulin-like growth factor I on metabolic and growth control in a patient with leprechaunism. J Clin Endocrinol Metab 1998;83:542-549.
37. Cheetham TD, Holly JM, Baxter RC, Meadows K, Jones J, Taylor AM, Dunger DB: The effects of recombinant human IGF-I administration on concentrations of acid labile subunit, IGF binding protein-3, IGF-I, IGF-II and proteolysis of IGF binding protein-3 in adolescents with insulin-dependent diabetes mellitus. J Endocrinol 1998;157:81-87.
38. Quattrin T, Thrailkill K, Baker L, Kuntze J, Compton P, Martha P, for rhIGF-I in IDDM Study Group: Improvement of HbA1c without increased hypoglycemia in adolescents and young adults with type 1 diabetes mellitus treated with recombinant human insulin-like growth factor-I and insulin. J Pediatr Endocrinol Metab 2001;14:267-277.
39. Labarta JI, Gargosky SE, Simpson DM, Lee PD, Argente J, Guevara-Aguirre J, Rosenfeld RG: Immunoblot studies of the acid-labile subunit in biological fluids, normal human serum and in children with GH deficiency and GH receptor deficiency before and after long-term therapy with GH or IGF-I respectively. Clin Endocrinol 1997;47:657-666.
40. Cornell HJ, Enberg G, Herington AC: Preferential association of the insulin-like growth factors I and II with metabolically inactive and active carrier-bound complexes in serum. Biochem J 1987;241:745-750.
41. Adams S, Moore J, Chu S, Bagi C, DeLeon L, Liu C, Schmidt D, Sommer A: Pharmacokinetics and bioavailability of rhIGF-I/IGFBP-3 in the rat and monkey. Prog Growth Factor Res 1995;6:347-356.
42. Lovett-Racke AE, Bittner P, Cross AH, Carlino JA, Racke MK: Regulation of experimental autoimmune encephalomyelitis with insulin-like growth factor (IGF-1) and IGF-1/IGF-binding protein-3 complex (IGF-1/IGFBP3). J Clin Invest 1998;101:1797-1804.
43. Roundtable on Research and Development of Drugs, Biologics, and Medical Devices. Rational Therapeutics for Infants and Children. Washington, National Academy Press, 2000.
44. Gurney H: Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative. J Clin Oncol 1996;14:2590-2611.
45. Frystyk J, Hussain M, Skjarbak C, Porksen N, Froesch ER, Orskov H: The pharmacokinetics of free insulin-like growth factor-I in healthy subjects. Growth Horm IGF Res 1999;9:150-156.
46. Mauras N, Quarmby V, Bloedow DC: Pharmacokinetics of insulin-like growth factor I in hypopituitarism: Correlation with binding proteins. Am J Physiol 1999;277:E579-E584.
47. Laron Z, Klinger B, Silbergeld A: Serum insulin-like growth factor-I (IGF-I) levels during long-term IGF-I treatment of children and adults with primary GH resistance (Laron syndrome). J Pediatr Endocrinol Metab 1999;12:145-152.
48. Longo N, Singh R, Elsas LJ: Decreased half-life of insulin-like growth factor I in Rabson-Mendelhall syndrome. J Inherit Metab Dis 2001;24:546-550.